Search

Your search keyword '"Stüssi G"' showing total 9 results
Start Over Author "Stüssi G" Journal hematological oncology
9 results on '"Stüssi G"'

1. IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA

Author

Condoluci, A., primary, Terzi‐di‐Bergamo, L., additional, Forestieri, G., additional, Moia, R., additional, Deambrogi, C., additional, Deodato, M., additional, Frustaci, A. M., additional, Merli, M., additional, Mattarucchi, R., additional, Autore, F., additional, Fahrni, G., additional, Scarfò, L., additional, Gussetti, D., additional, Bulian, P., additional, Zanatta, A., additional, Spina, V., additional, Faderl, M. R., additional, Bruscaggin, A., additional, Pini, K., additional, Piffaretti, D., additional, Koch, R., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Passweg, J., additional, Cavalli, F., additional, Zucca, E., additional, Gerber, B., additional, Gillessen, S., additional, Stüssi, G., additional, Gattei, V., additional, Ghia, P., additional, Gregor, M., additional, Laurenti, L., additional, Passamonti, F., additional, Tedeschi, A., additional, Gaidano, G., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

2. ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY

Author

Terzi di Bergamo, L, primary, Forestieri, G, additional, Loh, J. W, additional, Singh, A, additional, Spina, V, additional, Zucchetto, A, additional, Condoluci, A, additional, Faderl, M, additional, Koch, R, additional, Bruscaggin, A, additional, Pini, K, additional, Wu, W, additional, Piffaretti, D, additional, Bittolo, T, additional, Tissino, E, additional, Paoli, L, additional, Deambrogi, C, additional, Frustaci, A. M, additional, Autore, F, additional, Merli, M, additional, Scarfò, L, additional, Rasi, S, additional, Passweg, J, additional, Moia, R, additional, Martines, C, additional, Ghia, P, additional, Cavalli, F, additional, Zucca, E, additional, Gerber, B, additional, Gillessen, S, additional, Stüssi, G, additional, Montillo, M, additional, Passamonti, F, additional, Gregor, M, additional, Laurenti, L, additional, Tedeschi, A, additional, Gaidano, G, additional, Efremov, D, additional, Gattei, V, additional, Khiabanian, H, additional, and Rossi, D, additional

Published
2021
Full Text
View/download PDF

3. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA

Author

Spina, V., primary, Pirosa, M. C., additional, Bruscaggin, A., additional, Condoluci, A., additional, Pini, K., additional, Forestieri, G., additional, Zangrilli, I., additional, di Trani, M., additional, Kurlapski, M., additional, Moccia, A., additional, Moia, R., additional, Bulian, P., additional, Annunziata, S., additional, Borsatti, E., additional, Rodari, M., additional, Romanowicz, G., additional, Sacchetti, G. M., additional, Faderl, M., additional, Koch, R., additional, Piffaretti, D., additional, Terzi di Bergamo, L., additional, Stasia, A., additional, Cittone, M., additional, Chauvie, S., additional, Stüssi, G., additional, Gerber, B., additional, Stathis, A., additional, Sommer, S. Gillessen, additional, Cavalli, F., additional, Zucca, E., additional, Gattei, V., additional, Zaucha, J. M., additional, Pinto, A., additional, Gaidano, G., additional, Carlo‐Stella, C., additional, Hohaus, S., additional, Ceriani, L., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

4. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA

Author

Bonfiglio, F., primary, Bruscaggin, A., additional, Guidetti, F., additional, Terzi di Bergamo, L., additional, Faderl, M., additional, Spina, V., additional, Condoluci, A., additional, Bonomini, L., additional, Forestieri, G., additional, Koch, R., additional, Piffaretti, D., additional, Pini, K., additional, Pirosa, M. C., additional, Cittone, M. G., additional, Arribas, A., additional, Lucioni, M., additional, Ghilardi, G., additional, Wu, W., additional, Arcaini, L., additional, Baptista, M. J., additional, Bastidas, G., additional, Bea, S., additional, Boldorini, R., additional, Broccoli, A., additional, Canzonieri, V., additional, Cascione, L., additional, Ceriani, L., additional, Cogliatti, S., additional, Derenzini, E., additional, Devizzi, L., additional, Dietrich, S., additional, Elia, A. R., additional, Facchetti, F., additional, Gaidano, G., additional, Garcia, J. F., additional, Gerber, B., additional, Ghia, P., additional, Silva, M. G., additional, Gritti, G., additional, Guidetti, A., additional, Hitz, F., additional, Inghirami, G., additional, Ladetto, M., additional, Lopez‐Guillermo, A., additional, Lucchini, E., additional, Maiorana, A., additional, Marasca, R., additional, Matutes, E., additional, Meignin, V., additional, Merli, M., additional, Moccia, A., additional, Mollejo, M., additional, Montalban, C., additional, Novak, U., additional, Oscier, D. G., additional, Passamonti, F., additional, Piazza, F., additional, Pizzolitto, S., additional, Sabattini, E., additional, Salles, G., additional, Santambrogio, E., additional, Scarfó, L., additional, Stathis, A., additional, Stüssi, G., additional, Geyer, J. T., additional, Tapia, G., additional, Thieblemont, C., additional, Tousseyn, T., additional, Tucci, A., additional, Visco, C., additional, Vitolo, U., additional, Zenz, T., additional, Zinzani, P. L., additional, Khiabanian, H., additional, Calcinotto, A., additional, Bertoni, F., additional, Bhagat, G., additional, Campo, E., additional, Leval, L., additional, Dirnhofer, S., additional, Pileri, S. A., additional, Piris, M. Án., additional, Traverse‐Glehen, A., additional, Tzankov, A., additional, Paulli, M., additional, Ponzoni, M., additional, Mazzucchelli, L., additional, Cavalli, F., additional, Zucca, E., additional, and Rossi, D., additional

Published
2021
Full Text
View/download PDF

5. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A)

Author

Condoluci, A., primary, Terzi di Bergamo, L., additional, Langerbeins, P., additional, Hoechstetter, M., additional, Herling, C., additional, De Paoli, L., additional, Delgado, J., additional, Gentile, M., additional, Doubek, M., additional, Mauro, F.R., additional, Chiodin, G., additional, Mattsson, M., additional, Bahlo, J., additional, Cutrona, G., additional, Kotaskova, J., additional, Deambrogi, C., additional, Moia, R., additional, Gerber, B., additional, Zucca, E., additional, Ghielmini, M., additional, Cavalli, F., additional, Stüssi, G., additional, Neri, A., additional, Ferrarini, M., additional, Rosenquist, R., additional, Forconi, F., additional, Foà, R., additional, Pospisilova, S., additional, Morabito, F., additional, Wierda, W.G., additional, Montserrat, E., additional, Gaidano, G., additional, Hallek, M., additional, and Rossi, D., additional

Published
2019
Full Text
View/download PDF

6. Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

Author

Bruscaggin, A., primary, Spina, V., additional, Di Trani, M., additional, Martini, M., additional, Locatelli, S., additional, Cupelli, E., additional, Forestieri, G., additional, Condoluci, A., additional, Cuccaro, A., additional, Moccia, A., additional, Stathis, A., additional, Manzoni, M., additional, Deambrogi, C., additional, Diop, F., additional, Stüssi, G., additional, Cavalli, F., additional, Bertoni, F., additional, Zucca, E., additional, Larocca, L.M., additional, Gaidano, G., additional, Hohaus, S., additional, Carlo-Stella, C., additional, and Rossi, D., additional

Published
2017
Full Text
View/download PDF

7. EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME.

Author

Frustaci, A. M., Montillo, M., Rossi, D., Zinzani, P. L., Motta, M., Gaidano, G., Quaresmini, G., Scarfò, L., Pietrasanta, D., Coscia, M., Deodato, M., Zamprogna, G., Cairoli, R., Stüssi, G., Zucca, E., Pileri, S., Zenz, T., and Tedeschi, A.

Subjects
RICHTER syndrome, ATEZOLIZUMAB, VENETOCLAX, DIFFUSE large B-cell lymphomas, DNA repair
Abstract

RS mutation profile was tested on pre-treatment cell free DNA. Rate of unmeasurable MRD and impact of mutations and chronic lymphocytic leukemia-RS clonal relation on outcomes will be presented at the meeting. B Introduction: b Chemoimmunotherapy is the standard first line treatment of diffuse large B-cell lymphoma (DLBCL) variant of Richter syndrome (RS). [Extracted from the article]

Published
2023
Full Text
View/download PDF

8. Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS.

Author

Facchinelli D, Ciliberti E, Stüssi G, Ceriani L, and Zucca E

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Male, Neuralgia drug therapy, Neuralgia etiology, Neurolymphomatosis etiology, Prognosis, Central Nervous System Neoplasms complications, Lymphoma, Large B-Cell, Diffuse complications, Neuralgia pathology, Neurolymphomatosis pathology, Sciatic Nerve pathology, Testicular Neoplasms complications
Published
2020
Full Text
View/download PDF

9. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.

Author

Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stüssi G, Ghilardi G, and Gerber B

Subjects
Adult, Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Bone Marrow metabolism, Bone Marrow pathology, Drug Resistance, Neoplasm, Female, Humans, Immunoglobulin Light-chain Amyloidosis mortality, Infections etiology, Infections therapy, Male, Middle Aged, Recurrence, Retreatment, Severity of Illness Index, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Immunoglobulin Light-chain Amyloidosis diagnosis, Immunoglobulin Light-chain Amyloidosis drug therapy, Lymphocyte Count, Plasma Cells pathology
Abstract

Daratumumab, an anti-CD38 antibody, is effective in AL amyloidosis with low tumor burden. Data of daratumumab treatment in patients with AL amyloidosis but high tumor burden (≥10% bone marrow plasma cells) are limited. We report retrospective data of 10 consecutive patients with high tumor burden treated with daratumumab for relapsed/refractory AL amyloidosis. The median age at diagnosis was 62.3 years; all patients had cardiac involvement, and six (60%) patients had renal involvement. Median bone marrow plasma cell infiltration was 15% (range 10%-40%), and the median difference between involved and noninvolved free light-chains (dFLC) was 446 mg/L (range 102-1392 mg/L). Patients had a median of three prior lines of therapy, including bortezomib in all patients and lenalidomide in seven (70%) patients. The median time to first hematological response was 14 days (range 7-28 days), and the median time to best hematological response was 64 days (range 7-301 days). The hematological overall response was 90%, with high-quality response (≥ very good partial remission [VGPR]) in 70% of the patients. Fifty percent of the patients had a cardiac response after a median of 3.8 months (range 0.7-9.1). Infusion-related adverse events ≤ grade 2 occurred in seven (70%) patients and grade 3 adverse events in one patient. After a median follow-up time of 10 months, eight (80%) patients continued to receive daratumumab. We conclude that daratumumab is a very effective and safe treatment option in AL patients with relapsed/refractory disease and high disease burden at diagnosis. Daratumumab leads to rapid disease control and improvement of organ function., (©2019 John Wiley & Sons, Ltd.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results